Australia markets open in 2 hours 46 minutes

CannPal Animal Therapeutics Limited (CP1.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1550-0.0100 (-6.06%)
At close: 3:57PM AEDT

CannPal Animal Therapeutics Limited

45a Bay Street
Level 3
Double Bay, NSW 2028
61 2 6108 3622

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Layton Patrick MillsFounder, MD & Director224.9kN/AN/A
Dr. Margaret CurtisHead of Clinical Devel. and R&D187.15kN/AN/A
Mr. Baden Maxwell BowenCFO & Company Sec.N/AN/AN/A
Dr. Rayson TanChief Scientific Officer & Member of Advisory BoardN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.

Corporate governance

CannPal Animal Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.